REDWOOD CITY, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center. Four of the studies analyze Oncotype DX®, the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.
Following are details for each embargoed session (all times are in Central Standard Time):
Poster discussion (Poster Discussion 1 and Reception): "Prediction of 10-year chemotherapy benefit and breast cancer-specific survival by the 21-gene Recurrence Score (RS) assay in node-positive, ER-positive breast cancer - An update of SWOG-8814 (INT0100)"
Presenter: Kathy S. Albain, M.D., Professor, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Director, Breast Clinical Research Program, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.
Location: Ballroom A
Poster presentation (Poster Session II): "Effect of 21-Gene Recurrence Score Results on Treatment Recommendations in Patients with Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer"
Presenter: Ruth Oratz, M.D., NYU School of Medicine, New York, NY
Location: Exhibit Halls A-B
|SOURCE Genomic Health|
Copyright©2009 PR Newswire.
All rights reserved